Cargando…

Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model

BACKGROUND: Tuberculosis (TB) of the spine is a highly disruptive disease, especially in underdeveloped and developing countries. This condition requires standard TB treatment for 9–18 months, which increases patient risk of drug-resistant TB. Consequently, this raises the concern of adopting additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Siregar, Otman, Lelo, Aznan, Rahyussalim, Ahmad Jabir, Ilyas, Syafruddin, Benny, Kurniawati, Tri, Augustinus, Yohanes, Hendra, Mandagi, Tommy, Zufar, Muhammad Luqman Labib, Fathurrahman, Irfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897918/
https://www.ncbi.nlm.nih.gov/pubmed/36743515
http://dx.doi.org/10.1155/2023/7421325
_version_ 1784882343624835072
author Siregar, Otman
Lelo, Aznan
Rahyussalim, Ahmad Jabir
Ilyas, Syafruddin
Benny,
Kurniawati, Tri
Augustinus, Yohanes
Hendra,
Mandagi, Tommy
Zufar, Muhammad Luqman Labib
Fathurrahman, Irfan
author_facet Siregar, Otman
Lelo, Aznan
Rahyussalim, Ahmad Jabir
Ilyas, Syafruddin
Benny,
Kurniawati, Tri
Augustinus, Yohanes
Hendra,
Mandagi, Tommy
Zufar, Muhammad Luqman Labib
Fathurrahman, Irfan
author_sort Siregar, Otman
collection PubMed
description BACKGROUND: Tuberculosis (TB) of the spine is a highly disruptive disease, especially in underdeveloped and developing countries. This condition requires standard TB treatment for 9–18 months, which increases patient risk of drug-resistant TB. Consequently, this raises the concern of adopting additional therapies to shorten the treatment duration, improve the efficacy of anti-TB drugs, and further decrease damage in the affected tissues and organs. Matrix metalloproteinase- (MMP-) 1 is a key regulator of the destruction of the extracellular matrix and associated proteins and is a new potential target for TB treatment research. In the present study, we investigated the effects of doxycycline as an MMP-1 inhibitor in patients with spondylitis TB. METHODS: Seventy-two New Zealand white rabbits with spondylitis TB were divided into 12 different groups based on incubation period (2, 4, 6, and 8 weeks) and doxycycline administration (without, 1 mg/kg body weight (BW), and 5 mg/kg BW). We observed the course of infection through the blood concentration changes and immunohistochemical examination of MMP-1, in addition to BTA staining, culture, polymerase chain reaction (PCR), and histopathological examination. RESULTS: Treatment with once daily 5 mg/kg BW doxycycline significantly improved the blood MMP-1 level (p < 0.05) compared with the placebo and 1 mg/kg BW doxycycline. A significantly reduced ongoing infection and a higher healing rate were demonstrated in rabbits with a higher doxycycline dose through BTA staining, culture, PCR, and histopathology. Various degrees of vertebral endplates, vertebral body, and intervertebral disc destruction were observed in 32 rabbits with positive histopathological findings, in addition to positive inflammatory cell infiltration, characterized by numerous lymphocytes, macrophages, and epithelial cells, as well as abundant granulation tissue and necrotic substances proximal to the inoculated vertebral area. Bone and intervertebral disc destructions were more apparent in the untreated rabbits. CONCLUSION: Our study demonstrated the potential of doxycycline as an adjunctive treatment in spondylitis TB. However, limitations remain regarding the differences in the pathogenesis and virulence of Mycobacterium tuberculosis between rabbit and human systems, sample size, and the dose-dependent effect of doxycycline. Further studies are needed to address these issues.
format Online
Article
Text
id pubmed-9897918
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-98979182023-02-04 Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model Siregar, Otman Lelo, Aznan Rahyussalim, Ahmad Jabir Ilyas, Syafruddin Benny, Kurniawati, Tri Augustinus, Yohanes Hendra, Mandagi, Tommy Zufar, Muhammad Luqman Labib Fathurrahman, Irfan Biomed Res Int Research Article BACKGROUND: Tuberculosis (TB) of the spine is a highly disruptive disease, especially in underdeveloped and developing countries. This condition requires standard TB treatment for 9–18 months, which increases patient risk of drug-resistant TB. Consequently, this raises the concern of adopting additional therapies to shorten the treatment duration, improve the efficacy of anti-TB drugs, and further decrease damage in the affected tissues and organs. Matrix metalloproteinase- (MMP-) 1 is a key regulator of the destruction of the extracellular matrix and associated proteins and is a new potential target for TB treatment research. In the present study, we investigated the effects of doxycycline as an MMP-1 inhibitor in patients with spondylitis TB. METHODS: Seventy-two New Zealand white rabbits with spondylitis TB were divided into 12 different groups based on incubation period (2, 4, 6, and 8 weeks) and doxycycline administration (without, 1 mg/kg body weight (BW), and 5 mg/kg BW). We observed the course of infection through the blood concentration changes and immunohistochemical examination of MMP-1, in addition to BTA staining, culture, polymerase chain reaction (PCR), and histopathological examination. RESULTS: Treatment with once daily 5 mg/kg BW doxycycline significantly improved the blood MMP-1 level (p < 0.05) compared with the placebo and 1 mg/kg BW doxycycline. A significantly reduced ongoing infection and a higher healing rate were demonstrated in rabbits with a higher doxycycline dose through BTA staining, culture, PCR, and histopathology. Various degrees of vertebral endplates, vertebral body, and intervertebral disc destruction were observed in 32 rabbits with positive histopathological findings, in addition to positive inflammatory cell infiltration, characterized by numerous lymphocytes, macrophages, and epithelial cells, as well as abundant granulation tissue and necrotic substances proximal to the inoculated vertebral area. Bone and intervertebral disc destructions were more apparent in the untreated rabbits. CONCLUSION: Our study demonstrated the potential of doxycycline as an adjunctive treatment in spondylitis TB. However, limitations remain regarding the differences in the pathogenesis and virulence of Mycobacterium tuberculosis between rabbit and human systems, sample size, and the dose-dependent effect of doxycycline. Further studies are needed to address these issues. Hindawi 2023-01-27 /pmc/articles/PMC9897918/ /pubmed/36743515 http://dx.doi.org/10.1155/2023/7421325 Text en Copyright © 2023 Otman Siregar et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Siregar, Otman
Lelo, Aznan
Rahyussalim, Ahmad Jabir
Ilyas, Syafruddin
Benny,
Kurniawati, Tri
Augustinus, Yohanes
Hendra,
Mandagi, Tommy
Zufar, Muhammad Luqman Labib
Fathurrahman, Irfan
Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title_full Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title_fullStr Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title_full_unstemmed Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title_short Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model
title_sort doxycycline as a potential mmp-1 inhibitor for the treatment of spondylitis tuberculosis: a study in rabbit model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897918/
https://www.ncbi.nlm.nih.gov/pubmed/36743515
http://dx.doi.org/10.1155/2023/7421325
work_keys_str_mv AT siregarotman doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT leloaznan doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT rahyussalimahmadjabir doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT ilyassyafruddin doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT benny doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT kurniawatitri doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT augustinusyohanes doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT hendra doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT mandagitommy doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT zufarmuhammadluqmanlabib doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel
AT fathurrahmanirfan doxycyclineasapotentialmmp1inhibitorforthetreatmentofspondylitistuberculosisastudyinrabbitmodel